Pharma BD Deal Intelligence
The $2.65B Servier acquisition of Edgewise's muscular dystrophy business hands it sevasemten, a fast skeletal myosin inhibitor in pivotal Becker trials with Duchenne data pending, though $1.1B of the value sits in unproven Duchenne approval and $550M sales milestones.
Servier buys into muscular dystrophy with potentially $2.7B deal. Servier agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to…
Servier to spend up to $2.65B on Edgewise muscular dystrophy drugs. StockTitan reported Servier's agreement to acquire Edgewise's muscular dystrophy business…
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal. Edgewise shares jumped 17.9% to an all-time high after announcing the sevasemten…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
On June 1, 2026, Servier agreed to acquire the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up to $2.65 billion, comprising a $1.55 billion upfront payment and up to $1.1 billion in regulatory and commercial milestones. The transaction transfers global rights to sevasemten, an orally administered fast skeletal myosin inhibitor in a pivotal Becker muscular dystrophy cohort and a Phase 2 Duchenne muscular dystrophy study, along with related IP, regulatory filings and clinical data. Milestones include up to $200 million tied to Becker labeling, $600 million on Duchenne U.S. approval, and $300 million on annual U.S. net sales exceeding $550 million. The deal is expected to close in Q3 2026 subject to regulatory clearance; Edgewise retains its cardiovascular pipeline.
Becker muscular dystrophy (BMD) is an X-linked dystrophinopathy caused by in-frame mutations in the DMD gene that yield partially functional dystrophin, producing a milder, later-onset course than Duchenne. Progressive proximal weakness leads to loss of ambulation and cardiomyopathy. No disease-modifying therapy is approved; management is supportive.
Sevasemten is in the registrational GRAND CANYON/CANYON program in adult BMD (fully enrolled). Two-year open-label data showed stabilization of functional scores and reduced muscle-damage biomarkers; the program is the most advanced in BMD.
Duchenne muscular dystrophy (DMD) is the most common and severe childhood dystrophinopathy, caused by out-of-frame DMD mutations and near-absent dystrophin. Boys typically lose ambulation by early adolescence with respiratory and cardiac failure. Standard of care includes corticosteroids and approved exon-skipping/gene therapies for genotype subsets.
Sevasemten is in Phase 2 (DUNE/ARCH/FOX) development in DMD as a mutation-agnostic muscle-protective agent.
Servier agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65B ($1.55B upfront + up to $1.1B milestones), gaining global rights to sevasemten, an oral fast skeletal myosin inhibitor in a registrational Becker MD program and Phase 2 in Duchenne MD. Edgewise retains its cardiovascular pipeline. Closing expected Q3 2026 (subject to HSR).
Per Edgewise's transaction press release (June 1, 2026), the GRAND CANYON pivotal cohort of sevasemten in Becker muscular dystrophy is fully enrolled with 175 participants and powered at >98% to deliver a statistically significant difference versus placebo, with top-line data expected in Q4 2026. A positive readout would be the key catalyst for the up-to-$200M Becker labeling milestone within the Servier transaction and underpins the deal thesis.
Transaction between Servier and Edgewise Therapeutics is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Edgewise Therapeutics, Inc. (this deal) | 2026 | $2.6B | 75 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Aitia | 2024 | — | — |
| Servier / AmoyDx | 2024 | — | — |
| Servier / kyron.bio | 2026 | — | — |
← Browse all deals · How we score deals
More: 2026 deals · Servier deals · Neurology deals